Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

10 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzVXWY4OiCq NXHxTVAzTE2VTx?= MojTTWM2OD1yLkCwNFA4KM7:TR?= M4n1c|E4QTV4MEiw
K562 NUnafVhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXezZXp{PzJiaB?= MUjEUXNQ NWrSXmNjUUN3ME2wMlAxOSEQvF2= NGPQ[GsyPzl3NkC4NC=>
M07e NUDReXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHUVGVNPzJiaB?= NV:1TlFPTE2VTx?= Ml;zTWM2OD1yLkCwNVIh|ryP NWjkV4k1OTd7NU[wPFA>
ALL3 MWLDfZRwfG:6aXOgRZN{[Xl? MnHvNE4y|ryP MYq3NkBp MmXZSG1UVw>? NF;adWFKSzVyPUCuNFAxPCEQvF2= NEHuWIkyQTh6OUW0NC=>
CML MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGyNEBucW5? MkHCSG1UVw>? NULyS2UxUUN3ME2wMlAxOSEQvF2= M2K0UlE6OjF7MEG2
BA/F3 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r5[|czKGh? MknPSG1UVw>? M4D1TmlEPTB;Nj61PFkh|ryP NG\MdmgzOzB6OE[0OC=>
BA/F3 NUPJS3M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnaeWc4OiCq NFLIVZJFVVOR MVnJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?= MWCyN|A5QDZ2NB?=
BA/F3 Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUO3NkBp M{XWfWROW09? NIP0fVNKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP NH:weGMzOzB6OE[0OC=>
BA/F3 NXG3SplET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVu3NkBp NXnucnVFTE2VTx?= MmnyTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP MWKyN|A5QDZ2NB?=
BA/F3 M{PLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG1O|IhcA>? M{LJS2ROW09? M3H2dmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP NFT3UmUzOzNyMUewNy=>
BA/F3 NHLTPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH4Rmg4OiCq NFLoOppFVVOR M3vuOWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP M17C[VI{OzBzN{Cz
BA/F3 MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4flOVczKGh? M3K3NmROW09? NHn1SnBKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= NHnRV2QzOzNyMUewNy=>
BA/F3 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLwfVZ6PzJiaB?= MVfEUXNQ MV3JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO NIjOfFQzOzNyMUewNy=>
BA/F3 NHzYTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LtRlczKGh? MUHEUXNQ M1TPcGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{|ryP NFTuNXAzOzNyMUewNy=>
BA/F3 M{XDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHGO|IhcA>? M{\pPGROW09? Mo\VTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0> M3POclI{OzBzN{Cz
BA/F3 M3fOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3aO|IhcA>? NF21dHdFVVOR NULy[IVwUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2= M3[3c|I{OzBzN{Cz
BA/F3 NHe2RYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M165e|czKGh? M4LMOmROW09? M{j4eWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO NEXLOWMzOzNyMUewNy=>
BA/F3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:3NkBp MmjkSG1UVw>? NUfZcIVRUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN MmjlNlM{ODF5MEO=
T cell NUXyUnBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPzWXBFPzJiaB?= M3S3S2ROW09? NYTIZ29lUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1? NX7LOWEyOTdzNUS1NVI>
WiDr NV\DcI1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:3NkBp MWjEUXNQ MX3JR|UxRTBwMEWyJO69VQ>? M37TbVE2PjF3NUGy
PC3 NYfW[XBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljOO|IhcA>? MYPEUXNQ MUXJR|UxRTBwMEC5OEDPxE1? MVqxOVYyPTVzMh?=
MDA-MB-231 NWHDbWF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HaXFczKGh? NHfVcVJFVVOR MlPiTWM2OD1yLkCxNkDPxE1? MW[xOVYyPTVzMh?=
Hs578T NW\KR2RiS3m2b4TvfIlkKEG|c3H5 MWe3NkBp M1O0WWROW09? NUTxWG91T0l3ME2wMlA{KM7:TR?= Mmq0NlQxOTV|Mke=
HMEC NVLSPW5vS3m2b4TvfIlkKEG|c3H5 NXLa[nNsPzJiaB?= M3fjU2ROW09? MX3HTVUxRTFwODFOwG0> MoPlNlQxOTV|Mke=
DU145 MUjDfZRwfG:6aXOgRZN{[Xl? MnW2O|IhcA>? M335VmROW09? NHzrcnVIUTVyPUCuNVYh|ryP M1u4W|I1ODF3M{K3
U251 NGHTdIFEgXSxdH;4bYMhSXO|YYm= M4W5TFczKGh? MnPYSG1UVw>? M4DkTWdKPTB;Mj64NUDPxE1? MWWyOFAyPTN{Nx?=
NCI60 NYHyOIxsS3m2b4TvfIlkKEG|c3H5 NIXDcpU4OiCq NHH2SJpFVVOR MWjHTVUxRTVwNzFOwG0> M3n0SVI1ODF3M{K3
MALME-3M NWXaco9tS3m2b4TvfIlkKEG|c3H5 MVO3NkBp MVjEUXNQ NX;jZ2EyT0l3ME22MlYyKM7:TR?= MVeyOFAyPTN{Nx?=
KM12 MnXlR5l1d3SxeHnjJGF{e2G7 M1LTSFczKGh? NVKxZ|BETE2VTx?= NIDjdZNIUTVyPUeuOFQh|ryP MmLONlQxOTV|Mke=
SW620 MmjWR5l1d3SxeHnjJGF{e2G7 MYm3NkBp M1j2S2ROW09? M4DWWGdKPTB;OD60N{DPxE1? Mke5NlQxOTV|Mke=
RXF 393NL NEHCXGREgXSxdH;4bYMhSXO|YYm= NFj5Smk1KGSjeYO= NV7zeJRRTE2VTx?= NE\teXhKSzVyPUCuNFIyPyEQvF2= M4rne|I{OjV|MEe0
LXFA 983L M4jSNGN6fG:2b4jpZ{BCe3OjeR?= MkPDOEBl[Xm| NH\HVGhFVVOR MVTJR|UxRTBwMEW2OUDPxE1? MX6yN|I2OzB5NB?=
PRXF DU145 MVXDfZRwfG:6aXOgRZN{[Xl? NXHmSVVXPCCmYYnz MV;EUXNQ MYrJR|UxRTBwME[yN{DPxE1? NV\JXWpzOjN{NUOwO|Q>
PAXF 1657L NHTMb|JEgXSxdH;4bYMhSXO|YYm= NGDtT|E1KGSjeYO= NWTHcHVOTE2VTx?= NWnJRotIUUN3ME2wMlEzOSEQvF2= NG[4OFkzOzJ3M{C3OC=>
CXF 1103L NFjNR3pEgXSxdH;4bYMhSXO|YYm= MoXBOEBl[Xm| MXnEUXNQ M{ixTGlEPTB;ND6zOkDPxE1? M1HsVFI{OjV|MEe0
GXF251L NGH1OINEgXSxdH;4bYMhSXO|YYm= MUC0JIRigXN? MXXEUXNQ MmjHTWM2OD1{LkK1JO69VQ>? NH\udIczOzJ3M{C3OC=>
NCI-H23 NGfLUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne5O|IhcA>? M33tOGROW09? NXjIbo5RUUN3ME2yMlI4KM7:TR?= NEmzW2MzOzV{MUCyNC=>
HCT116 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVG3NkBp NFfHZ21FVVOR NYPZRmZtUUN3ME2yMlMh|ryP MoG1NlM2OjFyMkC=
MCF7 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fr[|czKGh? M1m3UmROW09? Mm\ETWM2OD1{LkW3JO69VQ>? Mn7TNlM2OjFyMkC=
NCI-H460 NEjjWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:ySFczKGh? M2DW[2ROW09? NHz3XYNKSzVyPUiuPVkh|ryP MomwNlM2OjFyMkC=
DLD1 NU\VU5lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fLUlczKGh? M2jrdGROW09? M4e5[2lEPTB;ND62JO69VQ>? MXGyN|U3Pzl4MB?=
NCI-H661 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjjbXc4OiCq NV7XNHpUTE2VTx?= MXXJR|UxRTdwODFOwG0> M4DWU|I{PTZ5OU[w
A549 Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTDR3AzPzJiaB?= MYDEUXNQ MVLJR|UxRThwMjFOwG0> NV;rd|hROjN3Nke5OlA>
U937 NFj1ZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP5TGhTPzJiaB?= NH\mcYdFVVOR NFy5PWdKSzVyPUGyMlIh|ryP M4\3dVI{PTZ5OU[w
HEK293 M3vHU2Z2dmO2aX;uJGF{e2G7 MlrFNVDDqM7:TR?= MnfISG1UVw>? NWew[od4UW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0> MXiyNlc4ODZzMB?=
HUVEC NWjobVFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS0NE4yPcLizszN MlvuO|IhcA>? MXfEUXNQ NILzbldKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> NEHsWWczOjh3M{m5Ny=>
HUVEC MmLKSpVv[3Srb36gRZN{[Xl? NHu3N2MyPcLizszN MYG3NkBp MnG1SG1UVw>? MYDJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=> NFL1WG4zOjh3M{m5Ny=>
Plasmodium falciparum M3LyZWZ2dmO2aX;uJGF{e2G7 NIe4fnIyOMLizszN M3y3R|E2KG2rbh?= MXrEUXNQ MkPiTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO MlnqNlQ2PTB|M{C=
PC3 MYjGeY5kfGmxbjDBd5NigQ>? MYmwMlEh|ryP M1S3b|UhcA>? MWPEUXNQ MYrJcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1? M{[4c|E6PDZ{OUe1
DU145 MoL3SpVv[3Srb36gRZN{[Xl? MkfuNE4yKM7:TR?= MlqxOUBp MmLBSG1UVw>? M{\HXGlvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7N MVexPVQ3Ojl5NR?=
PC3 MYnLbY5ie2ViQYPzZZk> Ml\QNE4yKM7:TR?= M3vDd|UhcA>? M1XKN2ROW09? NILiNpZKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N MVKxPVQ3Ojl5NR?=
DU145 MUnLbY5ie2ViQYPzZZk> MlHJNE4yKM7:TR?= MYq1JIg> Mn6xSG1UVw>? MmD3TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N NYfVSnJWOTl2NkK5O|U>
PC3 NFOzW3ZMcW6jc3WgRZN{[Xl? M1jBOVAvOSEQvF2= NELnO3U2KGh? NFjlcI1FVVOR NGDVW4lKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? NILNOFcyQTR4Mkm3OS=>
DU145 NUXFcoVWU2mwYYPlJGF{e2G7 MXOwMlEh|ryP NEnTPXE2KGh? NXvt[lZCTE2VTx?= NWfLb|l6UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= M2mwbVE6PDZ{OUe1
Huh7 NV3zemZzSW62aY\pdoFtKEG|c3H5 MoL1Nk42KM7:TR?= NFHOO5o1KGSjeYO= MXHEUXNQ MXnJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? NH\iXIIyPzN4ME[3Oi=>
C6/36 MVHBcpRqfmm{YXygRZN{[Xl? MnPuNk42KM7:TR?= M3fCS|Qh\GG7cx?= Ml;0SG1UVw>? MVjJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO M3K2R|E4OzZyNke2
U937 M2HKVmZ2dmO2aX;uJGF{e2G7 NFvJNowyKM7:TR?= MmLONUBp MVLEUXNQ NVfteWJKWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= NVj5[o1xOTd4OESwPVk>
U937 M3XkVWZ2dmO2aX;uJGF{e2G7 MoDYNUDPxE1? MUSxJIg> MXPEUXNQ MWjS[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> MYmxO|Y5PDB7OR?=
murine mast cell MXfGeY5kfGmxbjDBd5NigQ>? NFX5Vm8yKM7:TR?= MY[yOEBp M2TyWGROW09? NVS5foVxUW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W|ZTDtZZN1KGOnbHzzJIF1KDFidV2= MWGxO|Y5PDB7OR?=
BV-173 NUK3dI9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMECwNFAxOTB7IN88US=> Mm\5V2FPT0WU
K-562 NHm1WXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy0eoxvUUN3ME2wMlAxODByMEK2OkDPxE1? M3LaSHNCVkeHUh?=
BL-70 NUD3OXE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMECwNFAxQDJ{IN88US=> NVe0[m91W0GQR1XS
EM-2 MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnhTWM2OD1yLkCwNFAxOTB6IN88US=> MX7TRW5ITVJ?
LAMA-84 M4XIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2wTWM2OD1yLkCwNFAxOzJzIN88US=> M37hRnNCVkeHUh?=
MEG-01 NIrVVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn6bmVKSzVyPUCuNFAxODB7ODFOwG0> MmixV2FPT0WU
EoL-1-cell MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHxTWM2OD1yLkCwNFAyOzFizszN NWiwU2NkW0GQR1XS
CTV-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMECwNFQxPCEQvF2= MUTTRW5ITVJ?
TE-15 NYj1Rm5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEC1PFkh|ryP NGDyb2xUSU6JRWK=
NOS-1 NFG5TVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXqOnR4UUN3ME2wMlAxPjF|IN88US=> MYrTRW5ITVJ?
D-336MG M{Prfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLBTWM2OD1yLkCwOlMh|ryP MXjTRW5ITVJ?
LB1047-RCC NXeyfFRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLuT2gzUUN3ME2wMlAxQTh7IN88US=> M1\5TnNCVkeHUh?=
LB996-RCC NF2yNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEC5PVEh|ryP MWPTRW5ITVJ?
SW982 NX72WFhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnNTWM2OD1yLkCxNVE2KM7:TR?= NYf2WWJRW0GQR1XS
TK10 MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi4VWJKSzVyPUCuNFEyPzRizszN MV;TRW5ITVJ?
A704 M{jhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLvTWM2OD1yLkCxOFkyKM7:TR?= NVXNPZNDW0GQR1XS
TE-8 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW4UGN{UUN3ME2wMlAyPTd4IN88US=> MXzTRW5ITVJ?
DOHH-2 NHHaRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HYcWlEPTB;MD6wNVcyQSEQvF2= MVTTRW5ITVJ?
HOP-62 NXjreWozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEG4N|Qh|ryP Mn\LV2FPT0WU
TE-12 NUiyemJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHqXWVKSzVyPUCuNFE5PjFizszN NWnPbGV1W0GQR1XS
KGN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEG5OFIh|ryP MmDHV2FPT0WU
NCI-H1648 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH3NFBKSzVyPUCuNFIxOTFizszN M1\PWHNCVkeHUh?=
OS-RC-2 NX71N|B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nnRmlEPTB;MD6wNlA{KM7:TR?= NVO4dXJ1W0GQR1XS
GB-1 NWDiW25qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEKxOVch|ryP M{PNe3NCVkeHUh?=
RXF393 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLRTWM2OD1yLkCyN|U4KM7:TR?= MYHTRW5ITVJ?
LC-2-ad NIjkWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LyNGlEPTB;MD6wNlU5PiEQvF2= NEPCSYlUSU6JRWK=
KS-1 NFvaSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEK3N{DPxE1? M2jIN3NCVkeHUh?=
ETK-1 M2rLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC5VllEUUN3ME2wMlAzQDN{IN88US=> M4W0[HNCVkeHUh?=
SW954 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMEK5Nlch|ryP M1ywZXNCVkeHUh?=
Becker NU\FVGdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMEOwNFMh|ryP NWDEV|RTW0GQR1XS
MZ1-PC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEOxNVkh|ryP MUnTRW5ITVJ?
ES6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMEOxPVMh|ryP NV;EPXlsW0GQR1XS
KURAMOCHI M2TnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMEO0PFch|ryP M1HjdXNCVkeHUh?=
CGTH-W-1 M3izU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGyVYhKUUN3ME2wMlA{PTR6IN88US=> NWLWfZVjW0GQR1XS
VA-ES-BJ MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;xRmFKSzVyPUCuNFM6ODJizszN NEfoRZZUSU6JRWK=
LXF-289 MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnDTWM2OD1yLkCzPVU3KM7:TR?= NHr4[5VUSU6JRWK=
MPP-89 NF75[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jOSWlEPTB;MD6wOFA1QSEQvF2= MWrTRW5ITVJ?
SW872 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG2Wo1JUUN3ME2wMlA1OTZzIN88US=> Mn7jV2FPT0WU
SNB75 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DLVmlEPTB;MD6wOFQ{PSEQvF2= M125WnNCVkeHUh?=
PSN1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMES0O|Qh|ryP MVnTRW5ITVJ?
LB831-BLC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jPcGlEPTB;MD6wOFYxQSEQvF2= NVSxWINMW0GQR1XS
MFH-ino NWr6WVdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm1R|duUUN3ME2wMlA1PzJ2IN88US=> MVTTRW5ITVJ?
TGBC24TKB M33QSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzITWM2OD1yLkC0O|YyKM7:TR?= Mn3oV2FPT0WU
A388 M4nGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDZTGxKSzVyPUCuNFUxQTVizszN MWPTRW5ITVJ?
BB30-HNC M{L1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEW0N|ch|ryP M4PyWnNCVkeHUh?=
GI-ME-N MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f5SmlEPTB;MD6wOlEyQCEQvF2= NIPENolUSU6JRWK=
TGBC1TKB NEK2[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwME[xOlQh|ryP NF22eYhUSU6JRWK=
TE-10 NGe2[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn0fnNKSzVyPUCuNFY{PTdizszN NE\4[ZJUSU6JRWK=
A498 M3P2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rQV2lEPTB;MD6wO|I5PCEQvF2= MoqzV2FPT0WU
TE-11 NF2wR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3tSmhKSzVyPUCuNFc5PThizszN M4nVfXNCVkeHUh?=
BB65-RCC NFq1dmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEiyNlch|ryP NVXzOIx{W0GQR1XS
C2BBe1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvM[3NKSzVyPUCuNFg{ODhizszN MXnTRW5ITVJ?
NCI-H747 NV;w[WVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEizOlIh|ryP NVLTdlZOW0GQR1XS
IST-MES1 NXjGR|EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPtc5BWUUN3ME2wMlA5PTV{IN88US=> M1;6cnNCVkeHUh?=
KALS-1 MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXoclZKSzVyPUCuNFk1QSEQvF2= NHqzeIRUSU6JRWK=
GCIY MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nPVmlEPTB;MD6wPVY2PiEQvF2= MkPHV2FPT0WU
RL95-2 NXW3VJgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMUCzPEDPxE1? Mnv5V2FPT0WU
TE-1 M1j0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUC1OEDPxE1? NX:2VHR1W0GQR1XS
NCI-H1355 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn5TWM2OD1yLkGxNFI5KM7:TR?= M1jLRXNCVkeHUh?=
SW962 MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;XZmlEPTB;MD6xNVI6OiEQvF2= M33DXHNCVkeHUh?=
KLE MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;a[WlEPTB;MD6xNVMyPyEQvF2= NGLPepJUSU6JRWK=
MC116 NGX2O3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMUG0NUDPxE1? MWPTRW5ITVJ?
NMC-G1 NV;wdG8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jTUmlEPTB;MD6xNVYxPiEQvF2= NETOXW5USU6JRWK=
KU812 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K4RWlEPTB;MD6xNVg5OyEQvF2= M3jz[3NCVkeHUh?=
COLO-829 MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzP[HVOUUN3ME2wMlEzOjF|IN88US=> NG\JPFZUSU6JRWK=
NTERA-S-cl-D1 M3Tse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO0[4xPUUN3ME2wMlEzOjh|IN88US=> M17mSXNCVkeHUh?=
IST-MEL1 NV\6c41PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHKTWM2OD1yLkGzOFUh|ryP NX:3cHdUW0GQR1XS
MLMA NHTT[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMUSwN|Ih|ryP Ml70V2FPT0WU
LS-123 NFXP[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G5b2lEPTB;MD6xOFA3PCEQvF2= NFvnWFVUSU6JRWK=
LB2518-MEL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMUSxOlIh|ryP NYfqWlgzW0GQR1XS
NB69 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMUS0N|Yh|ryP MX3TRW5ITVJ?
8-MG-BA MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m3NmlEPTB;MD6xOVQ2QCEQvF2= NITacYZUSU6JRWK=
K5 MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zN[GlEPTB;MD6xOlQ5QSEQvF2= M{\WNHNCVkeHUh?=
KINGS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DJcWlEPTB;MD6xOlY3PiEQvF2= MkPLV2FPT0WU
SF268 NV;sfJk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXaOpNrUUN3ME2wMlE4PDB2IN88US=> NGD0OnhUSU6JRWK=
PF-382 NYG3cWZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG0PGZxUUN3ME2wMlE4Pjd6IN88US=> M1O4XHNCVkeHUh?=
SH-4 NYD6T5d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6yWJdJUUN3ME2wMlE5PDF|IN88US=> NHjnWpBUSU6JRWK=
NALM-6 M{H3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\hRWlEPTB;MD6xPVI6PSEQvF2= NY\NNnNHW0GQR1XS
CP66-MEL MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMUm1N|Eh|ryP MmXTV2FPT0WU
697 M3j5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrudmhJUUN3ME2wMlE6QTh5IN88US=> M2G0N3NCVkeHUh?=
CP67-MEL Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrMdmI3UUN3ME2wMlIxPDh6IN88US=> MWnTRW5ITVJ?
DSH1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnvTWM2OD1yLkK0NFAyKM7:TR?= MYjTRW5ITVJ?
HCE-4 NFuwUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMk[0N|kh|ryP MkTsV2FPT0WU
MZ2-MEL M4fUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMki1N|ch|ryP M1u5fXNCVkeHUh?=
BL-41 M{HmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvQWIhKUUN3ME2wMlI6OTJ|IN88US=> MlvSV2FPT0WU
HUTU-80 M3\5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwM{G0NkDPxE1? NFTtN4ZUSU6JRWK=
LOXIMVI NHv1WnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKzTWM2OD1yLkOxOVA{KM7:TR?= M4PTU3NCVkeHUh?=
no-10 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;HTYR5UUN3ME2wMlMyQTNzIN88US=> MUfTRW5ITVJ?
KARPAS-422 M{HROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDqTWM2OD1yLkOzPVk4KM7:TR?= MlfhV2FPT0WU
SW684 M2LJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWyfY5KSzVyPUCuN|Q6QCEQvF2= M3G4UXNCVkeHUh?=
SF126 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnBTWM2OD1yLkO1OFEh|ryP M4rONXNCVkeHUh?=
D-263MG NW\4Z3h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrabnJCUUN3ME2wMlM3OjJ2IN88US=> M4SySnNCVkeHUh?=
OVCAR-4 MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwM{e0N|Mh|ryP MkLkV2FPT0WU
BB49-HNC NXy0eGVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHJdWpwUUN3ME2wMlM5PTl7IN88US=> Mlq4V2FPT0WU
ONS-76 M2jESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwNEK5OVEh|ryP NFvDS3JUSU6JRWK=
MZ7-mel MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwNEe5NVEh|ryP MkXVV2FPT0WU
RCC10RGB MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33UOGlEPTB;MD60PVEyKM7:TR?= MoDtV2FPT0WU
BOKU MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPPSnpKSzVyPUCuOFkyOzNizszN M335S3NCVkeHUh?=
no-11 Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf5SFljUUN3ME2wMlUxOjJ6IN88US=> NELNR2FUSU6JRWK=
IST-SL2 M{DZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;0OIFbUUN3ME2wMlUxOzB{IN88US=> M{\pVnNCVkeHUh?=
RKO M4noZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nsNGlEPTB;MD61Nlk3PiEQvF2= MVvTRW5ITVJ?
HT-144 NGjz[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LwemlEPTB;MD61N|YxQSEQvF2= MljjV2FPT0WU
NCI-H446 M3jHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXQd3BKSzVyPUCuOlI4PiEQvF2= MmC5V2FPT0WU
QIMR-WIL NYfPNXZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\JPWlEPTB;MD63NFYzQSEQvF2= MWDTRW5ITVJ?
MHH-PREB-1 M1fVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvVTWM2OD1yLke0OFY6KM7:TR?= NFjvZ2RUSU6JRWK=
EW-16 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInmSVBKSzVyPUCuO|YyPzhizszN NH;YPZJUSU6JRWK=
EW-24 M{nQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDkV2JKSzVyPUCuO|gyPjVizszN MkPzV2FPT0WU
LB373-MEL-D M1nTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjhPFlKSzVyPUCuPFI2ODhizszN NW\wVlRwW0GQR1XS
TE-9 M4ryTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwOEe1N|Ih|ryP NXHJPGZbW0GQR1XS
A3-KAW NHvpblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vzc2lEPTB;MD65PFQ2OiEQvF2= NH\vS4RUSU6JRWK=
A101D NIXC[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwMEOwOFMh|ryP MnzHV2FPT0WU
OCUB-M M2\n[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37VO2lEPTB;MT6wOFQyOiEQvF2= NVvyVIpJW0GQR1XS
ES4 Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW0[od{UUN3ME2xMlA2OTR3IN88US=> M{HCPXNCVkeHUh?=
TE-6 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHjcmZtUUN3ME2xMlIyOjJ4IN88US=> MmrCV2FPT0WU
D-502MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMkOzO|Yh|ryP NXXsfmxSW0GQR1XS
KNS-42 NEnKUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjpNIt2UUN3ME2xMlI1PDF{IN88US=> MVrTRW5ITVJ?
SNU-C2B NYW1TmpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jrdWlEPTB;MT6zNFU5QSEQvF2= M2TxSHNCVkeHUh?=
NCI-H1838 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPsTWM2OD1zLkOwO|M{KM7:TR?= NWLGc5dvW0GQR1XS
NKM-1 M3TEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2mxPGlEPTB;MT6zNFg2QSEQvF2= NXyzdHhoW0GQR1XS
GI-1 NEHCNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml34TWM2OD1zLkO2NlIh|ryP M4XubHNCVkeHUh?=
NB5 M3TtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILIbYpKSzVyPUGuN|k5OjdizszN Mo\PV2FPT0WU
CAS-1 NF\YVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDuTWM2OD1zLkSwPVkzKM7:TR?= NVjR[XJCW0GQR1XS
HCE-T NXTIeIE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFwNU[3NVQh|ryP NHPUelBUSU6JRWK=
SBC-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPmdGtKSzVyPUGuOVc6QDRizszN M4niTXNCVkeHUh?=
JiyoyeP-2003 NW\PR3R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPmWVNKSzVyPUGuO|M1PjZizszN M4XJVHNCVkeHUh?=
TE-5 NXGxd4ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fGXGlEPTB;MT63PVE{QSEQvF2= M{HpT3NCVkeHUh?=
CAN MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwOEKyOVIh|ryP NX7qfXdrW0GQR1XS
SK-UT-1 M3niN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPoUopLUUN3ME2yMlE3Pjl|IN88US=> NYPMSpNuW0GQR1XS
JVM-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwM{[yPFQh|ryP MXrTRW5ITVJ?
LB771-HNC NVvscpp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37nd2lEPTB;Mj61O|U2OSEQvF2= M2GySHNCVkeHUh?=
NCCIT Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fo[WlEPTB;Mj64OlYyPiEQvF2= NIDRdFBUSU6JRWK=
NCI-H2126 M1\ON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrFW4lCUUN3ME2yMlg4PTV{IN88US=> MmjXV2FPT0WU
Calu-6 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3wTWM2OD1|LkC1O|QyKM7:TR?= Mlu1V2FPT0WU
SK-LMS-1 M{T1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLJeVhKSzVyPUOuNVE5QDZizszN NEGw[nFUSU6JRWK=
ARH-77 M4nGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSzTWM2OD1|LkS2PVE2KM7:TR?= NGTqTpdUSU6JRWK=
NB17 Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXWzVYdOUUN3ME2zMlY{QDR5IN88US=> MWrTRW5ITVJ?
A253 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTNwN{OyOFYh|ryP MUXTRW5ITVJ?
OPM-2 Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK2TWM2OD12LkK3Olg2KM7:TR?= MoW2V2FPT0WU
MV-4-11 NXHodJlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLTTWM2OD12LkO2OFU1KM7:TR?= MnnRV2FPT0WU
SR MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PhVGlEPTB;ND60PVk2PCEQvF2= NXL4c2RRW0GQR1XS
KG-1 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rnOGlEPTB;ND62NFg1PSEQvF2= NXTnPYRKW0GQR1XS
OCI-AML2 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL2cFhKSzVyPUWuPFYyPTRizszN NILyeIZUSU6JRWK=
D-247MG MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jibWlEPTB;Nj6xNlUyQSEQvF2= NFz5V2FUSU6JRWK=
DJM-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;rWWlEPTB;Nj60PFU2QCEQvF2= MlfvV2FPT0WU
RPMI-6666 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnUW|hKSzVyPUeuNlcxPjdizszN NGDtfodUSU6JRWK=
KARPAS-45 M4rsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nEZWlEPTB;Nz61NVY4OSEQvF2= MkPmV2FPT0WU
LP-1 M2DTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTdwNUS3PFIh|ryP NFHQSHVUSU6JRWK=
RS4-11 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTdwNkW3PFch|ryP NVXGNFdEW0GQR1XS
DU-4475 NGPJ[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\rN2xKSzVyPUiuNlE3PTJizszN NUHyTJZDW0GQR1XS
MONO-MAC-6 NIjNdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLGeo5KSzVyPUiuNlcxPjZizszN NWOzUo81W0GQR1XS
NCI-SNU-16 NX[wbY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRThwNU[xNlgh|ryP MVnTRW5ITVJ?
SJSA-1 NGn5UGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPxe4xKSzVyPUiuO|I5ODVizszN M2rOeXNCVkeHUh?=
MMAC-SF NFfqcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;W[mJ7UUN3ME24Mlc6OzB5IN88US=> NFXGSohUSU6JRWK=
SK-NEP-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRThwOEmxOVUh|ryP MVXTRW5ITVJ?
J-RT3-T3-5 NFHLclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu4TWM2OD16Lkm2OVI6KM7:TR?= M4qyNXNCVkeHUh?=
SKM-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2njUWlEPTB;OT6wNVc{PCEQvF2= MVHTRW5ITVJ?
LB2241-RCC NFnqWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS1OZBxUUN3ME25MlAzODF{IN88US=> M{DKTnNCVkeHUh?=
SIG-M5 NVTuXGJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHDTWM2OD17LkCyOFk{KM7:TR?= MYnTRW5ITVJ?
EVSA-T MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXYbm5KSzVyPUmuNlc4QTNizszN NYC3[oVTW0GQR1XS
GT3TKB NWLD[2lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HmSWlEPTB;OT6zOVU1PiEQvF2= NF;xPXZUSU6JRWK=
NB6 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLzUHpKSzVyPUmuPVIzPTlizszN NWPRPYp6W0GQR1XS
EHEB M{m4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjVOZFKSzVyPUGwMlA3PTZizszN NH3TdFRUSU6JRWK=
HEL Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFyLkS3O|Yh|ryP NGDF[3JUSU6JRWK=
ALL-PO MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXpO4FbUUN3ME2xNE44QTN6IN88US=> NV3wO5N1W0GQR1XS
TGW MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm5TWM2OD1zMT6yPFI5KM7:TR?= NG\hfG9USU6JRWK=
BC-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13ZSGlEPTB;MUKuNVE{QCEQvF2= NYe0emY1W0GQR1XS
IA-LM M{DwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[4eGlEPTB;MUKuOFQ1PSEQvF2= NIDIXlRUSU6JRWK=
UACC-257 NWnrOVlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknxTWM2OD1zMj65NVk5KM7:TR?= MX\TRW5ITVJ?
KP-N-YS NHvCPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLheYxKSzVyPUGyMlkzQDNizszN MnjhV2FPT0WU
Raji M4fm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF|Lke0PVch|ryP MYPTRW5ITVJ?
SF539 NF3Q[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjhPGtKSzVyPUGzMlg2PTdizszN M1i0NHNCVkeHUh?=
DMS-153 NIXT[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnIWoQyUUN3ME2xOE4xODJ6IN88US=> NFnNXZVUSU6JRWK=
L-540 NWPjZnpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D3S2lEPTB;MUWuNFY4OiEQvF2= M13wUnNCVkeHUh?=
MN-60 NHv1cYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj3TWM2OD1zNT6xPVc6KM7:TR?= MmTMV2FPT0WU
RPMI-8866 NVG4N3FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF5LkS0OVQh|ryP NETqVI5USU6JRWK=
NCI-H510A NWjlZYtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f3UmlEPTB;MUmuN|k4OyEQvF2= MU\TRW5ITVJ?
NB13 NYTJd4MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF7LkS4O|ch|ryP M4L2R3NCVkeHUh?=
HAL-01 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\XbVRTUUN3ME2xPU44PTR|IN88US=> MnnRV2FPT0WU
NCI-H720 MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M171b2lEPTB;MkCuNlc{OyEQvF2= NHm0NoVUSU6JRWK=
REH NUP3emN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfJPVF[UUN3ME2yNE43OzV5IN88US=> NGnIdmNUSU6JRWK=
KNS-81-FD NFL5e4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3Eb3EzUUN3ME2yN{4yPDZizszN MUHTRW5ITVJ?
HC-1 M4GxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ2LkW1OVEh|ryP Mnv5V2FPT0WU
NCI-H2141 NXPQ[WpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHmTWM2OD1{ND63O|U1KM7:TR?= NFPaUZlUSU6JRWK=
MOLT-4 M1TRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvDUnJKSzVyPUK2MlY4PTNizszN M2\TTnNCVkeHUh?=
OMC-1 NGXXN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\ofolKSzVyPUK3MlE1OjJizszN NULIeHpmW0GQR1XS
LC-1F MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrEeG5KSzVyPUK3MlMzPDVizszN MXrTRW5ITVJ?
NCI-H1304 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7zNodKSzVyPUK4MlE3OjhizszN MmnFV2FPT0WU
BC-1 NG[w[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv0NGJ{UUN3ME2yPE43PTFizszN MV3TRW5ITVJ?
NCI-H64 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO4e3hXUUN3ME2yPU43OjV|IN88US=> MVXTRW5ITVJ?
MOLT-16 NHqw[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvnV21KSzVyPUK5MlYzQTJizszN M{LpcnNCVkeHUh?=
U-87-MG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rFWmlEPTB;M{CuO|Y3KM7:TR?= NILPO4NUSU6JRWK=
GAK MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoeyTWM2OD1|MT6yOlg3KM7:TR?= MX3TRW5ITVJ?
ES8 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTN{LkGyOVIh|ryP M1fscHNCVkeHUh?=
HCC1599 M2GxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOyW4pKSzVyPUOyMlM{OjVizszN NYD5doNvW0GQR1XS
EB-3 NGfER|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi4U2xKSzVyPUO0MlMyOTdizszN NU\3XVgyW0GQR1XS
HCC1187 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTN3LkiwOVIh|ryP NInFR|BUSU6JRWK=
SK-PN-DW NUHsSpR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXZTWM2OD1|Nj6xPVQ{KM7:TR?= MW\TRW5ITVJ?
JVM-3 Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\nTWM2OD1|Nz6yN|M5KM7:TR?= Mnr2V2FPT0WU
HCC2157 Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTSTmlHUUN3ME2zO{46QTR4IN88US=> NEjyem1USU6JRWK=
A4-Fuk M2HxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vHOmlEPTB;M{iuNVAxQSEQvF2= MVTTRW5ITVJ?
COR-L279 M33rdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTRyLkK4OVEh|ryP MUHTRW5ITVJ?
DEL M2nFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTRzLkmwPFYh|ryP MkXmV2FPT0WU
NCI-H1395 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;mS2lEPTB;NEKuNFE3OyEQvF2= NFPOb4tUSU6JRWK=
MHH-NB-11 M4XuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnuRWFKSzVyPUSzMlA5OThizszN MV\TRW5ITVJ?
NCI-H2107 NGXTbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rH[WlEPTB;NEOuOFg1PiEQvF2= NGPLN2tUSU6JRWK=
NEC8 MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrNNZhoUUN3ME20OE4{OzZizszN MYfTRW5ITVJ?
COLO-684 NGHveWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTR4LkKyOVgh|ryP MWPTRW5ITVJ?
LS-411N NHntbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTR6LkS3OFgh|ryP MYPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID